These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7507662)

  • 1. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu.
    Bossard MJ; Bergsma DJ; Brandt M; Livi GP; Eng WK; Johnson RK; Levy MA
    Biochem J; 1994 Jan; 297 ( Pt 2)(Pt 2):365-72. PubMed ID: 7507662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes.
    DeCenzo MT; Park ST; Jarrett BP; Aldape RA; Futer O; Murcko MA; Livingston DJ
    Protein Eng; 1996 Feb; 9(2):173-80. PubMed ID: 9005438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
    Chen J; Zheng XF; Brown EJ; Schreiber SL
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4947-51. PubMed ID: 7539137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus.
    Benton BM; Zang JH; Thorner J
    J Cell Biol; 1994 Nov; 127(3):623-39. PubMed ID: 7525596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
    Chiu MI; Katz H; Berlin V
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12574-8. PubMed ID: 7809080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.
    Koser PL; Eng WK; Bossard MJ; McLaughlin MM; Cafferkey R; Sathe GM; Faucette L; Levy MA; Johnson RK; Bergsma DJ; Livi GP
    Gene; 1993 Jul; 129(2):159-65. PubMed ID: 8325502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus).
    Itoh S; Navia MA
    Protein Sci; 1995 Nov; 4(11):2261-8. PubMed ID: 8563622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
    Sabatini DM; Erdjument-Bromage H; Lui M; Tempst P; Snyder SH
    Cell; 1994 Jul; 78(1):35-43. PubMed ID: 7518356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex.
    Futer O; DeCenzo MT; Aldape RA; Livingston DJ
    J Biol Chem; 1995 Aug; 270(32):18935-40. PubMed ID: 7642551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
    Stan R; McLaughlin MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP
    J Biol Chem; 1994 Dec; 269(51):32027-30. PubMed ID: 7528205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
    Lorenz MC; Heitman J
    J Biol Chem; 1995 Nov; 270(46):27531-7. PubMed ID: 7499212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand.
    Chakraborty TK; Weber HP; Nicolaou KC
    Chem Biol; 1995 Mar; 2(3):157-61. PubMed ID: 9383417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
    J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missense mutations at the FKBP12-rapamycin-binding site of TOR1.
    Freeman K; Livi GP
    Gene; 1996 Jun; 172(1):143-7. PubMed ID: 8654975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations.
    Silva ND; Prendergast FG
    Biophys J; 1996 Mar; 70(3):1122-37. PubMed ID: 8785272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin.
    Chambraud B; Radanyi C; Camonis JH; Shazand K; Rajkowski K; Baulieu EE
    J Biol Chem; 1996 Dec; 271(51):32923-9. PubMed ID: 8955134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mean field analysis of FKBP12 complexes with FK506 and rapamycin: implications for a role of crystallographic water molecules in molecular recognition and specificity.
    Rejto PA; Verkhivker GM
    Proteins; 1997 Jul; 28(3):313-24. PubMed ID: 9223178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling.
    Soman KV; Hanks BA; Tien H; Chari MV; O'Neal KD; Morrisett JD
    Protein Sci; 1997 May; 6(5):999-1008. PubMed ID: 9144770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chemistry of signal transduction.
    Clardy J
    Proc Natl Acad Sci U S A; 1995 Jan; 92(1):56-61. PubMed ID: 7529414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
    Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
    Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.